flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of disease. This new post-hoc analysis of SURPASS-CVOT's kidney shows greater kidney protection with tirzepatide (#mounjaro) FLOW trial Ozempic® (semaglutide injection)

Modulating the Immune Response Some studies suggest that GLP-1 agonists can influence immune cells , possibly reducing overactive immune reactions seen in conditions like asthma and allergies

Add bacteriostatic water slowly along the vial wall

Autophagy contributes to prolonging life span and health span in mammals (1013) by removing damaged organelles, allowing for the rejuvenation of cellular components

Directions : 1 Capsules 1-2 times per day

We therefore propose that tissue-associated oxidative stress may promote conversion of circulating TTR into dsNNTTR locally within the interstitial compartment, rather than exclusively during intracellular synthesis or processing